Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. more
Time Frame | BIIB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.78% | -2.06% | -0.55% |
1-Month Return | -7.06% | -1.92% | 2.72% |
3-Month Return | -25.71% | -10.4% | 7.66% |
6-Month Return | -34.37% | -4.6% | 10.15% |
1-Year Return | -41.36% | 4.06% | 27.53% |
3-Year Return | -38.05% | 1.94% | 32.31% |
5-Year Return | -50.51% | 36.48% | 89.2% |
10-Year Return | -58.5% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 14.38B | 13.44B | 10.98B | 10.17B | 9.84B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.51,"profit":true},{"date":"2021-12-31","value":76.38,"profit":true},{"date":"2022-12-31","value":70.76,"profit":true},{"date":"2023-12-31","value":68.41,"profit":true}] |
Cost of Revenue | 1.96B | 1.81B | 2.11B | 2.28B | 2.53B | [{"date":"2019-12-31","value":77.18,"profit":true},{"date":"2020-12-31","value":71.26,"profit":true},{"date":"2021-12-31","value":83.28,"profit":true},{"date":"2022-12-31","value":89.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 12.42B | 11.64B | 8.87B | 7.90B | 7.30B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.7,"profit":true},{"date":"2021-12-31","value":71.42,"profit":true},{"date":"2022-12-31","value":63.55,"profit":true},{"date":"2023-12-31","value":58.78,"profit":true}] |
Gross Margin | 86.40% | 86.57% | 80.79% | 77.61% | 74.24% | [{"date":"2019-12-31","value":99.8,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.32,"profit":true},{"date":"2022-12-31","value":89.64,"profit":true},{"date":"2023-12-31","value":85.76,"profit":true}] |
Operating Expenses | 5.39B | 7.19B | 6.06B | 4.99B | 6.01B | [{"date":"2019-12-31","value":74.89,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.3,"profit":true},{"date":"2022-12-31","value":69.42,"profit":true},{"date":"2023-12-31","value":83.49,"profit":true}] |
Operating Income | 7.04B | 4.55B | 2.84B | 2.32B | 2.10B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":64.61,"profit":true},{"date":"2021-12-31","value":40.34,"profit":true},{"date":"2022-12-31","value":32.95,"profit":true},{"date":"2023-12-31","value":29.78,"profit":true}] |
Total Non-Operating Income/Expense | 15.90M | 316.90M | (1.34B) | 174.10M | (770.90M) | [{"date":"2019-12-31","value":5.02,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-422.25,"profit":false},{"date":"2022-12-31","value":54.94,"profit":true},{"date":"2023-12-31","value":-243.26,"profit":false}] |
Pre-Tax Income | 7.13B | 5.05B | 1.75B | 3.59B | 1.30B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.83,"profit":true},{"date":"2021-12-31","value":24.49,"profit":true},{"date":"2022-12-31","value":50.4,"profit":true},{"date":"2023-12-31","value":18.2,"profit":true}] |
Income Taxes | 1.16B | 992.30M | 52.50M | 632.80M | 135.30M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.69,"profit":true},{"date":"2021-12-31","value":4.53,"profit":true},{"date":"2022-12-31","value":54.65,"profit":true},{"date":"2023-12-31","value":11.68,"profit":true}] |
Income After Taxes | 5.97B | 4.06B | 1.69B | 2.96B | 1.16B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":28.36,"profit":true},{"date":"2022-12-31","value":49.58,"profit":true},{"date":"2023-12-31","value":19.46,"profit":true}] |
Income From Continuous Operations | 5.97B | 4.06B | 1.69B | 2.96B | 1.16B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":28.36,"profit":true},{"date":"2022-12-31","value":49.63,"profit":true},{"date":"2023-12-31","value":19.46,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 5.89B | 4.00B | 1.56B | 3.05B | 1.16B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.94,"profit":true},{"date":"2021-12-31","value":26.43,"profit":true},{"date":"2022-12-31","value":51.74,"profit":true},{"date":"2023-12-31","value":19.72,"profit":true}] |
EPS (Diluted) | 33.64 | 32.82 | 19.18 | 18.45 | 15.08 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":97.56,"profit":true},{"date":"2021-12-31","value":57.02,"profit":true},{"date":"2022-12-31","value":54.85,"profit":true},{"date":"2023-12-31","value":44.83,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BIIB | |
---|---|
Cash Ratio | 0.31 |
Current Ratio | 1.26 |
Quick Ratio | 0.80 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BIIB | |
---|---|
ROA (LTM) | 4.99% |
ROE (LTM) | 10.47% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BIIB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.42 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BIIB | |
---|---|
Trailing PE | 13.62 |
Forward PE | 8.86 |
P/S (TTM) | 2.28 |
P/B | 1.34 |
Price/FCF | 27 |
EV/R | 2.80 |
EV/Ebitda | 9.62 |
PEG | 6.24 |
Biogen Inc (BIIB) share price today is $146.79
Yes, Indians can buy shares of Biogen Inc (BIIB) on Vested. To buy Biogen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIIB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biogen Inc (BIIB) via the Vested app. You can start investing in Biogen Inc (BIIB) with a minimum investment of $1.
You can invest in shares of Biogen Inc (BIIB) via Vested in three simple steps:
The 52-week high price of Biogen Inc (BIIB) is $268.3. The 52-week low price of Biogen Inc (BIIB) is $148.6.
The price-to-earnings (P/E) ratio of Biogen Inc (BIIB) is 13.6203
The price-to-book (P/B) ratio of Biogen Inc (BIIB) is 1.34
The dividend yield of Biogen Inc (BIIB) is 0.00%
The market capitalization of Biogen Inc (BIIB) is $21.95B
The stock symbol (or ticker) of Biogen Inc is BIIB